Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148082 | 1.00 | PTGES (0.41) | PTGESROCK2KMT2AMEN1BCHE | |
| SCHEMBL6978475 | 0.93 | MEN1 (0.40) | PTGESROCK2KMT2AMEN1BCHE | |
| SCHEMBL6978482 | 0.93 | MEN1 (0.40) | PTGESROCK2KMT2AMEN1BCHE | |
| SCHEMBL3141992 | 0.92 | PTGES (0.40) | PTGESROCK2KMT2AKDM1ARCOR1 | |
| SCHEMBL3141983 | 0.92 | PTGES (0.40) | PTGESROCK2KMT2AKDM1ARCOR1 | |
| SCHEMBL16685264 | 0.91 | ROCK2 (0.46) | PTGESROCK2KMT2AMEN1KDM1A | |
| SCHEMBL16685268 | 0.91 | ROCK2 (0.46) | PTGESROCK2KMT2AMEN1KDM1A | |
| SCHEMBL16685266 | 0.91 | ROCK2 (0.46) | PTGESROCK2KMT2AMEN1KDM1A | |
| SCHEMBL29354347 | 0.91 | ROCK2 (0.46) | PTGESROCK2KMT2AMEN1KDM1A | |
| SCHEMBL12700719 | 0.90 | PTGES (0.39) | PTGESROCK2KMT2AMEN1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| WO-2012118978-A1 | METHODS FOR TREATING ONCOVIRUS POSITIVE CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PTGES 3913/4885ROCK2 1718/4885KMT2A 4599/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PTGES 3926/4885ROCK2 1307/4885KMT2A 4506/4885 |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | TFEB, SQSTM1, ULK1 | PTGES 3713/4885ROCK2 2228/4885KMT2A 2591/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PTGES 3926/4885ROCK2 1307/4885KMT2A 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.